Wande Osuntokun

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

S. Neelakantham, V. Erpenbeck, M. Larbig, 2016, Clinical pharmacology in drug development.

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

Baldur P Magnusson, T. Popov, S. Weinstein, 2016, Data in brief.

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Baldur P Magnusson, Todor A Popov, S. Weinstein, 2016, Pulmonary pharmacology & therapeutics.

QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study

Baldur P Magnusson, Todor A Popov, S. Miller, 2015 .